In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.
--------
Question: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Medicare Identity Theft Prevention
Act of 2010''.

SEC. 2. PROHIBITION OF INCLUSION OF SOCIAL SECURITY ACCOUNT NUMBERS ON
MEDICARE CARDS.

(a) In General.--Section 205(c)(2)(C) of the Social Security Act
(42 U.S.C. 405(c)(2)(C)), as amended by section 1414(a)(2) of the
Patient Protection and Affordable Care Act (Public Law 111-148), is
amended by adding at the end the following new clause:
''(xi) The Secretary of Health and Human Services, in consultation
with the Commissioner of Social Security, shall establish cost-
effective procedures to ensure that a social security account number
(or any derivative thereof) is not displayed, coded, or embedded on the
Medicare card issued to an individual who is entitled to benefits under
part A of title XVIII or enrolled under part B of title XVIII and that
any other identifier displayed on such card is easily identifiable as
not being the social security account number (or a derivative
thereof).''.
(b) Effective Date.--
(1) In general.--The amendment made by subsection (a) shall
apply with respect to Medicare cards issued on and after an
effective date specified by the Secretary of Health and Human
Services, but in no case shall such effective date be later
than the date that is 24 months after the date adequate funding
is provided pursuant to subsection (d)(2).
(2) Reissuance.--Subject to subsection (d)(2), in the case
of individuals who have been issued such cards before such
date, the Secretary of Health and Human Services--
(A) shall provide for the reissuance for such
individuals of such a card that complies with such
amendment not later than 3 years after the effective
date specified under paragraph (1); and
(B) may permit such individuals to apply for the
reissuance of such a card that complies with such
amendment before the date of reissuance otherwise
provided under subparagraph (A) in such exceptional
circumstances as the Secretary may specify.
(c) Outreach Program.--Subject to subsection (d)(2), the Secretary
of Health and Human Services, in consultation with the Commissioner of
Social Security, shall conduct an outreach program to Medicare
beneficiaries and providers about the new Medicare card provided under
this section.
(d) Report to Congress and Limitations on Effective Date.--
(1) Report.--Not later than 90 days after the date of the
enactment of this Act, the Secretary of Health and Human
Services, acting through the Administrator of the Centers for
Medicare & Medicaid Services and in consultation with the
Commissioner of Social Security, shall submit to Congress a
report that includes detailed options regarding the
implementation of this section, including line-item estimates
of and justifications for the costs associated with such
options and estimates of timeframes for each stage of
implementation. In recommending such options, the Secretary
shall take into consideration, among other factors, cost-
effectiveness and beneficiary outreach and education.
(2) Limitation; modification of deadlines.--With respect to
the amendment made by subsection (a), and the requirements of
subsections (b) and (c)--
(A) such amendment and requirements shall not apply
until adequate funding is appropriated pursuant to
paragraph (3) to implement the provisions of this
section, as determined by Congress; and
(B) any deadlines otherwise established under this
section for such amendment and requirements are
contingent upon the receipt of adequate funding (as
determined in subparagraph (A)) for such
implementation.
The previous sentence shall not affect the timely submission of
the report required under paragraph (1).
(3) Authorization of appropriations.--
(A) In general.--In addition to any amounts made
available to the Secretary of Health and Human Services
for the Program Management Account of the Centers for
Medicare & Medicaid Services for administrative
expenses and to the Commissioner of Social Security for
administrative expenses, and subject to subparagraph
(B), taking into consideration the report submitted
under paragraph (1), there are authorized to be
appropriated such sums as are necessary to carry out
the previous subsections of this section, including
section 205(c)(2)(C)(xi) of the Social Security Act, as
added by subsection (a), for each of the five fiscal
years beginning after the date of submittal of the
report under paragraph (1).
(B) Limitation.--Such funds are not authorized to
be appropriated until after receipt of the report
provided under paragraph (1).

Answer: Medicare Identity Theft Prevention Act of 2010 - Amends title II (Old Age, Survivors and Disability Insurance) (OASDI) of the Social Security Act to direct the Secretary of Health and Human Services (HHS) to establish cost-effective procedures to ensure that: (1) a Social Security account number (or any derivative) is not displayed, coded, or embedded on the Medicare card issued to an individual entitled to benefits under part A (Hospital Insurance) of title XVIII (Medicare) of the Social Security Act or enrolled under Medicare part B (Supplementary Medical Insurance); and (2) any other identifier displayed on such card is easily identifiable as not being the Social Security account number (or a derivative).

Question: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Helping Effective Antibiotics Last
Act of 2015'' or the ''HEAL Act''.

SEC. 2. APPROVAL OF CERTAIN DRUGS FOR USE IN A WELL-DEFINED POPULATION
OF PATIENTS.

(a) Approval of Certain Antibacterial.--Section 505 of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 355) is amended by adding at
the end the following:
''(x) Approval of Certain Antibacterial Drugs for Use in a Well-
Defined Population of Patients.--
''(1) Unmet medical need defined.--In this subsection, the
term 'unmet medical need' means that the antibacterial drug
involved--
''(A) has improved efficacy, as demonstrated in
adequate, well-controlled studies in humans, for
specific diseases or conditions, where current
therapies have been shown to be less effective;
''(B) has clinically meaningful decreased harms,
demonstrated in adequate, well-controlled studies in
humans, for diseases or conditions, where current
therapies have unacceptable adverse effects; or
''(C) has improved convenience, as demonstrated in
adequate, well-controlled studies in humans, where
improved convenience results in improved effectiveness
or decreased harms.
''(2) Approval.--Upon receipt of an application under
subsection (b) for an antibacterial drug that is intended to
treat a serious or life-threatening disease or condition,
irrespective of whether the drug is intended to address an
unmet medical need, the Secretary--
''(A) may approve the drug under subsection (c)
only for treating a well-defined population of
patients, and based upon the results of clinical trials
inclusive of human subjects representative of such
well-defined population;
''(B) in determining whether to grant such
approval, shall rely on superior outcomes over
available therapies based on direct measures of patient
benefits, as demonstrated in adequate, well-controlled
studies in the well-defined patient population, such
as--
''(i) decreased mortality;
''(ii) irreversible morbidity; or
''(iii) validated surrogate endpoints that
reflect mortality or irreversible morbidity;
and
''(C) shall require the labeling of drugs approved
pursuant to this subsection to prominently include in
the prescribing information required by section 201.57
of title 21, Code of Federal Regulations (or any
successor regulation)--
''(i) the population of patients with
respect to which the added benefit over
available therapies is expected as studied in
adequate, well-controlled studies that form the
basis for approval; and
''(ii) the method for identifying members
of that population.
''(3) Risk evaluation and mitigation strategy.--The
Secretary--
''(A) shall require a risk evaluation and
mitigation strategy (REMS) under section 505-1 for each
drug approved under this subsection; and
''(B) may include in any such strategy additional
elements to assure the safe use of the drug under
subsections (e) and (f) of section 505-1.
''(4) Rule of construction.--Nothing in this subsection
shall be construed to alter the standards of evidence under
subsection (c) or (d) (including the substantial evidence
standard in subsection (d)). Subsections (c) and (d) and such
standards of evidence apply to the review and approval of drugs
under this subsection, including whether a drug is safe and
effective. Nothing in this subsection shall be construed to
limit the authority of the Secretary to approve products
pursuant to this Act and the Public Health Service Act as
authorized prior to the date of enactment of this subsection.
''(5) Effective immediately.--The Secretary shall have the
authorities vested in the Secretary by this subsection
beginning on the date of enactment of this subsection,
irrespective of when and whether the Secretary promulgates
final regulations to carry out this subsection.''.
(b) Licensure of Certain Biological Products.--Section 351(j) of
the Public Health Service Act (42 U.S.C. 262(j)) is amended--
(1) by striking ''(j)'' and inserting ''(j)(1)'';
(2) by inserting ''505(x),'' after ''505(p),''; and
(3) by adding at the end the following:
''(2) In applying section 505(x) of the Federal Food, Drug, and
Cosmetic Act to the licensure of biological products under this
section--
''(A) references to an antibacterial drug with added
benefits over available therapies for a well-defined population
that is intended to treat a serious or life-threatening disease
or condition shall be construed to refer to biological products
with added benefits over available therapies for a well-defined
population intended to treat a bacterial infection associated
with a serious or life-threatening disease; and
''(B) references to an application submitted under section
505(b) of such Act and to approval of a drug under section
505(c) of such Act shall be construed to refer to an
application submitted under subsection (a) of this section and
to licensure of a biological product under such subsection (a),
respectively.''.
(c) Monitoring.--Title III of the Public Health Service Act is
amended by inserting after section 317T (42 U.S.C. 247b-22) the
following:

''SEC. 317U. MONITORING OF ANTIBACTERIAL DRUG USE, PATIENT OUTCOMES,
AND RESISTANCE.

''(a) Monitoring.--The Secretary, acting through the Director of
the Centers for Disease Control and Prevention, shall use the National
Healthcare Safety Network or another appropriate monitoring system to
monitor--
''(1) changes in patient outcomes such as mortality and
irreversible morbidity causally related to antibacterial
resistance; and
''(2) changes in bacterial resistance to drugs in relation
to patient outcomes.
''(b) Public Availability of Data.--The Secretary, acting through
the Director of the Centers for Disease Control and Prevention, shall
make the data derived from monitoring under this section publicly
available for the purposes of--
''(1) improving the monitoring of important trends in
patient outcomes in relation to antibacterial resistance; and
''(2) ensuring appropriate stewardship of antibacterial
drugs, including those receiving approval or licensure for a
well-defined population pursuant to section 505(x) of the
Federal Food, Drug, and Cosmetic Act.''.

SEC. 3. SUSCEPTIBILITY TEST INTERPRETIVE CRITERIA FOR MICROBIAL
ORGANISMS.

(a) In General.--Section 511 of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 360a) is amended to read as follows:

''SEC. 511. SUSCEPTIBILITY TEST INTERPRETIVE CRITERIA FOR MICROBIAL
ORGANISMS.

''(a) In General.--The Secretary shall--
''(1) identify upon approval or licensing of antibacterial
drugs (including biological products intended to treat a
bacterial infection and other types of antimicrobial drugs, as
deemed appropriate by the Secretary), including qualified
infectious disease products, susceptibility test interpretive
criteria for such drugs based upon patient outcomes of
mortality and morbidity from adequate and well-controlled
studies and such other confirmatory evidence as the Secretary
deems necessary; and
''(2) update, consistent with subsection (b), such criteria
as needed based upon scientific evidence of changes in patient
outcomes.
''(b) Responding to Changes in Patient Outcomes To Evaluate
Susceptibility Test Interpretive Criteria.--
''(1) In general.--As needed based on evidence related to
changes in patient outcomes, the Secretary shall--
''(A) evaluate any new scientific studies on
changes in patient outcomes in relation to
susceptibility test interpretive criteria; and
''(B) publish on the public Website of the Food and
Drug Administration a notice--
''(i) presenting suggested new or updated
interpretive criteria; and
''(ii) if needed, hold a public advisory
committee to discuss scientific evidence
related to changes in interpretative criteria.
''(2) Annual compilation of notices.--Each year, the
Secretary shall compile the notices published under paragraph
(1)(B) noting any changes from prior notices and publish such
compilation in the Federal Register.
''(c) Definition.--In this section, the term 'susceptibility test
interpretive criteria' means one or more specific values which
characterize patient outcomes in relation to the degree to which
bacteria or other microbes are more resistant to treatment as measured
by patient outcomes.''.
(b) Conforming Amendment.--Section 1111 of the Food and Drug
Administration Amendments Act of 2007 (42 U.S.C. 247d-5a; relating to
identification of clinically susceptible concentrations of
antimicrobials) is repealed.
(c) Report to Congress.--Not later than one year after the date of
enactment of this Act, the Secretary of Health and Human Services shall
submit to the Committee on Energy and Commerce of the House of
Representatives and the Committee on Health, Education, Labor, and
Pensions of the Senate a report on the progress made in implementing
section 511 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
360a), as amended by this section.

SEC. 4. REQUIRING DEMONSTRATION OF SUPERIOR OUTCOMES FOR QUALIFIED
INFECTIOUS DISEASE PRODUCTS TO RECEIVE AN EXTENDED
EXCLUSIVITY PERIOD.

Section 505E(g) of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 355f(g)) is amended by striking ''means an antibacterial or
antifungal drug for human use intended to treat'' and inserting ''means
an antibacterial or antifungal drug for human use that is demonstrated
to produce superior outcomes over available therapies, based on direct
measures of patient benefits in clinical trials, and that is intended
to treat''.

SEC. 5. GUIDANCE ON TARGET PRODUCT PROFILES.

Not later than 18 months after the date of enactment of this Act,
the Commissioner of Food and Drugs, in consultation with the
Administrator of the Centers for Medicare & Medicaid Services, the
Director of the Indian Health Service, the Secretary of Defense, and
the Secretary of Veterans Affairs, shall issue guidance on the
development of target product profiles for novel antibacterial drugs
focused on public health priorities.

Answer: Helping Effective Antibiotics Last Act of 2015 or the HEAL Act This bill amends the Federal Food, Drug, and Cosmetic Act to allow the Food and Drug Administration (FDA) to approve an antibacterial drug or biological product that is intended to treat a serious or life-threatening condition only for treating a well-defined population of patients. To be approved, the antibacterial product must produce superior outcomes over available therapies in the well-defined patient population. A product approved by this pathway must include in its prescribing information the population of patients expected to benefit from using the product and the method for identifying members of that population. The FDA must require each product to have a risk evaluation and mitigation strategy. The Centers for Disease Control and Prevention must monitor changes to bacterial drug resistance and changes to patient outcomes caused by bacterial drug resistance. Upon approval of antibacterial products, the FDA must identify susceptibility test interpretive criteria (the drug concentrations where a type of bacteria is categorized as susceptible, intermediate, or resistant) and update the criteria as needed based upon evidence of changes in patient outcomes. To be eligible for an exclusivity period extension, a qualified infectious disease product must be demonstrated to produce superior outcomes over available therapies. The FDA must issue guidance on the development of target product profiles for antibacterial drugs.

Question: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Social Security Right To Know Act''.

SEC. 2. MATERIAL TO BE INCLUDED IN ANNUAL REPORT OF TRUSTEES.

Section 201(c) of the Social Security Act (42 U.S.C. 401(c)) is
amended--
(1) by redesignating paragraphs (1) through (5) as
subparagraphs (A) through (E), respectively;
(2) by striking ''under paragraph (2)'' and inserting
''under subparagraph (B)'';
(3) by inserting ''(1)'' after ''(c)'';
(4) by redesignating the undesignated text following
subparagraph (E) (as redesignated by paragraph (1) of this
section) as paragraph (2);
(5) by moving the last sentence of paragraph (2) (as
redesignated by paragraph (4) of this section) so that it
follows the fifth sentence of paragraph (1) (as redesignated by
paragraph (3) of this section);
(6)(A) by moving the text of the fifth sentence of
paragraph (2) (as redesignated by paragraph (4) of this
section) beginning with ''shall be printed'' and ending with
''report is made'' so that it follows ''above'' in the first
sentence of paragraph (2) (as redesignated by paragraph (4) of
this section);
(B) by striking the remainder of the fifth sentence of
paragraph (2) (as redesignated by paragraph (4) of this
section); and
(C) by inserting ''and'' after the text so moved;
(7) in the fourth sentence of paragraph (2) (as
redesignated by paragraph (4) of this section), by striking
''Such report shall also include an'' and inserting the
following:
''(C) An'';
(8) in the third sentence of paragraph (2) (as redesignated
by paragraph (4) of this section), by striking ''Such report
shall include an'' and inserting the following:
''(B) An'';
(9) in the first sentence of paragraph (2) (as redesignated
by paragraph (4) of this section)--
(A) by striking ''(2) above'' after ''paragraph''
and inserting ''(1)(B)''; and
(B) by striking ''shall include a statement'' and
inserting ''shall include the following:
''(A) A statement'';
(10) by inserting after subparagraph (C) (as redesignated
by paragraph (7) of this section) the following:
''(D) A statement, in terms of inflation-adjusted dollars,
present discounted value, and nominal dollars, of--
''(i) the aggregate amount of the unfunded long-
term projected liability of the social security system
and any change in that amount from the preceding year;
and
''(ii) the amount of deficit or surplus that the
social security system will run in the last year of
such long-term projection period, with any aggregate
assets or liabilities held by the Trust Funds in that
final projected year.
''(E) The economic model and relevant data used to make the
financial projections required to be reported under this
paragraph, including any changes in the model and data from the
preceding year.
''(F) A conspicuous summary of the items required by
clauses (i) and (ii) of subparagraph (D), in terms of
inflation-adjusted dollars.
''(G) An explanation that states in substance that the
Trust Funds balances reflect resources authorized by Congress
to pay future social security benefits, but do not consist of
real economic assets that can be used in the future to fund
benefits, and that such balances are claims against the United
States Treasury that, when redeemed, must be financed through
increased taxes, public borrowing, benefit reduction, or
elimination of other Federal expenditures.''.

SEC. 3. MATERIAL TO BE INCLUDED IN SOCIAL SECURITY ACCOUNT STATEMENT.

Section 1143(a) of the Social Security Act (42 U.S.C. 1320b-13(a))
is amended--
(1) in paragraph (2)(C) by striking ''and'';
(2) in paragraph (2)(D) by striking the period and
inserting ''; and'';
(3) in paragraph (2), by adding at the end the following
new subparagraph:
''(E)(i) as determined by the Chief Actuary of the Social
Security Administration--
''(I) a comparison of the annual social security
tax inflows (including amounts appropriated under
subsections (a) and (b) of section 201 of this Act and
section 121(e) of the Social Security Amendments of
1983 (26 U.S.C. 401 note)) to the amount paid in
benefits annually; and
''(II) a statement whether the ratio described in
subclause (I) will result in a cash flow deficit and
what year any such deficit will commence, as well as
the first year in which funds in the Federal Old-Age
and Survivors Insurance Trust Fund and the Federal
Disability Insurance Trust Fund will cease to be
sufficient to cover any such deficit and the percentage
of benefits due at that time that could be paid from
the annual social security tax inflows (as that term is
used in subclause (I));
''(ii) the explanation required by section 201(c)(2)(G);
and
''(iii) an explanation, in simple and easily understood
terms, of the average rate of return that a taxpayer can expect
to receive on old-age insurance benefits as compared to the
total amount of social security taxes a taxpayer expects to
pay, including the inflation-adjusted average rate of return
for workers born in every year beginning with 1900, set out in
chart or graph form, with an explanatory caption or legend, as
determined by the Chief Actuary of the Social Security
Administration.''.

SEC. 4. USE OF CONTINUOUS WORK HISTORY SAMPLE FOR STATISTICAL RESEARCH.

(a) Data To Be Made Available.--Notwithstanding any other provision
of law, the Social Security Administration shall make available to the
public the Continuous Work History Sample (referred to in this section
as the ''CWHS'') data administered by such Administration subject to
the restrictions provided for in subsections (b) and (c).
(b) Limitations on Release of Data.--The Office of Research and
Statistics of the Social Security Administration shall make statistical
samples of individual records from the CWHS available to a user if the
user--
(1) agrees to make use of the data from the CWHS solely for
the purpose of conducting statistical research activities;
(2) agrees in writing to such conditions as may be
reasonably determined by the Commissioner of the Social
Security Administration to be necessary to ensure that data
from the CWHS is not made available in individually
identifiable form; and
(3) fully reimburses the Office of Research and Statistics
for the cost of supplying the data.
(c) No Personally Identifiable Information.--To protect privacy,
the Office of Research and Statistics of the Social Security
Administration shall remove all identifiers which can link CWHS records
to the identity of an individual respondent prior to the release of the
data.
(d) Definitions.--In this section--
(1) the term ''Continuous Work History Sample'' means the
statistical sample of individual administrative records held by
the Social Security Administration; and
(2) the term ''user'' means any individual or legal entity,
including an employee of the Federal Government, who receives
access to the Continuous Work History Sample.

Answer:
Social Security Right To Know Act - Amends title II (Old Age, Survivors and Disability Insurance) (OASDI) of the Social Security Act to require a certain annual report by the Board of Trustees of the Federal Old-Age and Survivors and Disability Insurance Trust Funds on the operation and status of such Funds to include information on: (1) the unfunded long-term projected liability of the Social Security system and any change in such amount from the preceding year as well as the deficit or surplus that the system will run in the last year of the long-term projection period, with any aggregate assets or liabilities held by the Trust Funds in that final projected year; and (2) the economic model and relevant data used to make such projections.Requires Social Security account statements to contain: (1) a comparison of the annual Social Security tax inflows to the amount paid annually in benefits; and (2) a statement of whether the ratio will result in a cash flow deficit, what year such deficit will commence as well as the first year in which funds in the Trust Funds will cease to be sufficient to cover the deficit, and the percentage of benefits due at that time that could be paid from annual tax inflows. Requires account statements also to explain the average rate of return that a taxpayer can expect to receive on old- age insurance benefits as compared to the total amount of Social Security taxes a taxpayer expects to pay.Makes Social Security Administration Continuous Work History Sample data publicly available for statistical research purposes subject to certain limitations.